New York Life Investment Management LLC Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

New York Life Investment Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.4% during the 4th quarter, HoldingsChannel reports. The firm owned 54,873 shares of the medical research company’s stock after selling 9,227 shares during the period. New York Life Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $29,126,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. WCM Investment Management LLC boosted its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after acquiring an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. boosted its position in shares of Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after acquiring an additional 1,654 shares during the last quarter. DMC Group LLC boosted its position in shares of Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 84 shares during the last quarter. S. R. Schill & Associates boosted its position in shares of Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 792 shares during the last quarter. Finally, Check Capital Management Inc. CA acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $219,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $6.27 on Wednesday, hitting $574.99. The company’s stock had a trading volume of 1,171,929 shares, compared to its average volume of 1,549,559. The firm has a 50 day moving average of $574.58 and a two-hundred day moving average of $531.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock has a market cap of $219.48 billion, a price-to-earnings ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,277 shares of company stock worth $35,373,364. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TMO. Evercore ISI upped their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Raymond James upped their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. HSBC upped their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.